Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease

Clin Neurophysiol. 2006 Sep;117(9):1917-21. doi: 10.1016/j.clinph.2006.03.033. Epub 2006 Aug 1.

Abstract

Objective: To determine whether low-frequency repetitive transcranial magnetic stimulation (rTMS) may modulate l-DOPA-induced dyskinesia (LID) in dyskinetic Parkinson's disease (PD) patients. LID is a severe motor complication in advanced PD patients. The neural mechanisms involved in LID are not clear, and it is apparent that both an excessive decrease in internal pallidus firing and a modification and overactivation of cortical motor and premotor areas are involved in its pathogenesis.

Methods: Using low frequency 1Hz repetitive rTMS we investigated whether decrease of excitability of the supplementary motor area (SMA) may result in modification of LID in PD patients. Furthermore we tested whether it was possible to enhance and/or prolong the beneficial effects of the treatment with repeated sessions of stimulation.

Results: We observed that 1Hz rTMS induced a transient reduction of dyskinesias. A single session of rTMS improved LID, while repeated sessions of stimulation failed to enhance and/or prolong the beneficial effects of the procedure, without causing motor deterioration or other adverse effects.

Conclusions: These results suggest that LID may depend on an increased excitability of the SMA.

Significance: SMA rTMS is effective in reducing transiently LID, although cannot yet be considered clinically useful.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Aged
  • Analysis of Variance
  • Antiparkinson Agents / adverse effects
  • Chi-Square Distribution
  • Dyskinesia, Drug-Induced / etiology
  • Dyskinesia, Drug-Induced / pathology*
  • Dyskinesia, Drug-Induced / therapy*
  • Female
  • Humans
  • Levodopa / adverse effects
  • Male
  • Middle Aged
  • Motor Cortex / physiopathology*
  • Motor Cortex / radiation effects
  • Parkinson Disease / drug therapy
  • Time Factors
  • Transcranial Magnetic Stimulation / methods*
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Levodopa